Department of Nephrology and Hypertension, Barzilai University Medical Center, 2 Hahistadrut St, Ashkelon 78278, Israel.
Division of Nephrology, Baylor College of Medicine, Houston, TX, USA.
Ther Adv Chronic Dis. 2015 Sep;6(5):252-63. doi: 10.1177/2040622315589934.
Ferric citrate is a novel phosphate binder that allows the simultaneous treatment of hyperphosphatemia and iron deficiency in patients being treated for end-stage renal disease with hemodialysis (HD). Multiple clinical trials in HD patients have uniformly and consistently demonstrated the efficacy of the drug in controlling hyperphosphatemia with a good safety profile, leading the US Food and Drug Administration in 2014 to approve its use for that indication. A concurrent beneficial effect, while using ferric citrate as a phosphate binder, is its salutary effect in HD patients with iron deficiency being treated with an erythropoietin-stimulating agent (ESA) in restoring iron that becomes available for reversing chronic kidney disease (CKD)-related anemia. Ferric citrate has also been shown in several studies to diminish the need for intravenous iron treatment and to reduce the requirement for ESA. Ferric citrate is thus a preferred phosphate binder that helps resolve CKD-related mineral bone disease and iron-deficiency anemia.
柠檬酸铁是一种新型的磷酸盐结合剂，可同时治疗接受血液透析（HD）治疗的终末期肾病患者的高磷血症和缺铁症。多项 HD 患者的临床试验一致证明了该药物在控制高磷血症方面的疗效，且安全性良好，这促使美国食品和药物管理局于 2014 年批准将其用于该适应症。在使用柠檬酸铁作为磷酸盐结合剂时，同时存在有益的作用，即其对接受促红细胞生成素刺激剂（ESA）治疗缺铁的 HD 患者具有有益作用，可恢复铁，从而可逆转慢性肾脏病（CKD）相关贫血。几项研究还表明，柠檬酸铁可减少静脉铁治疗的需求，并降低 ESA 的需求。因此，柠檬酸铁是一种首选的磷酸盐结合剂，有助于解决 CKD 相关的矿物质骨病和缺铁性贫血。
